[D-p-Cl-Phe6,Leu17]-VIP

FAPI-04

68Ga-Fapi-04

(177Lu)-DOTA-fapi-04

HYINC-FAPI 04

N-[2-[(2S)-2-cyano-4,4-difluoropyrrolidin-1-yl]-2-oxoethyl]-6-methoxyquinoline-4-carboxamide

NTFAPI

FAPI-46

NOTA-FAPI-46

6-[3-[4-(2-aminoacetyl)piperazin-1-yl]propoxy]-N-[2-(2-cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethyl]quinoline-4-carboxamide

FAPI-05

FAPI-06

FAPI-07

FAPI-08

FAPI-09

FAPI-10

FAPI-11

FAPI-12

FAPI-14

FAPI-15

FAPI-2

(S)-6-[3-(4-Boc-1-piperazinyl)propoxy]-N-[2-(2-cyano-4,4-difluoro-1-pyrrolidinyl)-2-oxoethyl]quinoline-4-carboxamide

FAPI-SH

NH2-UAMC1110

UAMC1110

(S)-N-(2-(2-cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethyl)-6-(3-(piperazine-1-yl)propoxy)quinoline-4-carboxamide

FAPI02

(R)-N-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)-6-hydroxyquinoline-4-carboxamide

tert-butyl 6-(3-(4-Boc-piperazin-1-ypropyl-1-(methyl)amino)quinoline-4-carboxylate

N-(2-(2-cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethyl)-6-(3-(4-Boc-piperazin-1-yl)propyl-1-(methyl)amino)quinoline-4-carboxamide

NOTA-P-FAPI

NOTA-FAPT

FAPI-34

68Ga-Fapi

Gd-FAPI04

OncoFAP

FAP-PI3KI1

Fluorogen binding modulator-1

FAP Ligand (FL)

(S)-N-(2-(2-cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethyl)-6-(methyl(3-(piperazin-1-yl)propyl)amino)quinoline-4-carboxamide

(S)-4-(4-(3-((4-((2-(2-cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethyl)carbamoyl)quinolin-6-yl)oxy)propyl)piperazin-1-yl)-4-oxobutanoic acid

NOAT-Suc-EDA-OncoFAP

FAPI -74

Mal-C2-FAPI

Boc-FAPI 04-COOH

LNC1007

DOTA-Suc-Lys-(FAPI-04)2